Latest Safety News

Orezone Gold Corporation reported solid Q3 2025 results with strong liquidity and on-track hard rock expansion, setting the stage for a significant production boost in 2026.

Orica Limited has delivered its strongest financial performance in over a decade, driven by premium product demand and digital innovation, while advancing ambitious sustainability targets. The company signals continued growth for 2026 despite emerging supply chain challenges.

Orica Limited has reported its strongest earnings in over a decade, with a 23% rise in EBIT to $992 million and a 32% jump in net profit before significant items. The company also increased its share buy-back program and declared a higher dividend, signaling confidence in its growth strategy and sustainability commitments.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Orica Limited reported a 6% increase in revenue to AUD 8.14 billion and a 23% rise in EBIT to AUD 992.2 million for FY2025, alongside record safety performance and significant strides in decarbonisation.

Spacetalk Ltd has secured an $877k R&D tax refund for FY2025, more than doubling last year’s amount, underscoring its strategic pivot to software and a 20% growth in recurring revenue.

The FDA's removal of the black box warning on hormone replacement therapies marks a pivotal shift for Mayne Pharma, potentially unlocking new market opportunities and reshaping women’s health treatment.

Actinogen Medical’s XanaMIA Phase 2b/3 trial for Alzheimer’s disease has received a positive safety recommendation from its independent Data Monitoring Committee, allowing the study to proceed unchanged. Investors now await the critical efficacy analysis scheduled for January 2026.

Radiopharm Theranostics has successfully enrolled the second cohort in its Phase 1 trial of 177Lu-RAD204, with the Data Safety Monitoring Committee greenlighting a dose increase to 90mCi for the third cohort. Early results show promising tumor targeting and safety in multiple advanced cancers.

Neurotech International has received a $4.73 million R&D tax incentive refund, reinforcing its clinical development efforts in paediatric neurological disorders. The funds will support ongoing trials and working capital needs.

Volt Group Limited is set to acquire 4D Delta, a Perth-based leader in digital asset inspection technology, in a $7.25 million deal that promises to diversify Volt’s offerings and boost recurring revenues in the mineral processing sector.

dorsaVi Limited has acquired a cutting-edge neuromorphic processing-in-memory technology portfolio, positioning itself at the forefront of next-generation wearable and robotics intelligence. This strategic move, coupled with leadership changes, signals a new era for the company’s adaptive biosensor and robotics platforms.